Ultime notizie per Hologic (NASDAQ:HOLX) Azioni

Hologic

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Hologic Inc

Needham analyst Mike Matson reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Buy and maintains $90 price target.

News

Price Target

Reiteration

Analyst Ratings

HOLX

Needham Reiterates Buy on Hologic, Maintains $90 Price Target

On Monday, Hologic Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) agreed to acquire&nbsp;&nbsp;Gynesonics, Inc. for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41310959/hologic-to-acquire-gynesonics-developer-of-minimally-invasive-solutions-for-womens-health" rel="noreferrer noopener">approximately $350 million</a>.
Gynesonics is a privately held medical device company that develops minimally invasive solutions for women&#8217;s health.
California-based Gynesonics develops and sells the Sonata System, a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.
The Sonata System combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39534064/womens-health-focused-hologic-has-significant-capacity-for-expansion-via-m-a-bullis" rel="noreferrer noopener">Women&#8217;s Health-Focused Hologic Has Significant Capacity For Expansion Via M&amp;A, Bullish Analyst Says</a>.
William Blair writes that Sonata System&#8217;s approach differs from Hologic&#8217;s Acessa device/ procedure, which delivers imaging and radiofrequency heat through two small abdominal incisions.
Hologic&#8217;s MyoSure device/procedure is also a solution for fibroid removal, though this is done through tissue removal rather than tissue ablation. &#8220;We believe that while there could become overlap amongst these products, having different solutions in Hologic&#8217;s product suite should allow for greater adoption,&#8221; the analyst writes.
Given the target&#8217;s profile, William Blair analyst says it is unlikely that the deal will significantly impact Hologic&#8217;s objective of maintaining operating margins in the low-30% range.
Hologic is scheduled to report fiscal fourth-quarter<a target="_blank" href="https://www.benzinga.com//node/41183593" rel="noreferrer noopener"> earnings in early November.</a>
As per data from Benzinga Pro, analysts expect adjusted EPS of $1.01 and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">revenues of $977.05 million</a>.
The analyst adds that revenue and earnings forecasts and consensus estimates have decreased in the past month as the company signals a more cautious stance on non-core elements like net interest expense.
The company is well-positioned to achieve mid-single-digit organic revenue growth, with earnings growth projected to outpace that in the high-single- to low-double-digit percentage range over time.
Several factors could drive earnings within this expected range, and shares are trading at a fair multiple of just under 19 times 2025 earnings.
The analyst reiterates <a target="_blank" href="https://www.benzinga.com/quote/HOLX/analyst-ratings" rel="noreferrer noopener">the Outperform rating</a>.
Price Action: HOLX stock is up 1.54% at $81.04 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41317937/qualcomm-set-for-50-surge-in-snapdragon-8-gen-4-shipments-by-late-2024-analyst-pred" target="_blank" rel="noreferrer noopener">Qualcomm Set For 50% Surge In Snapdragon 8 Gen 4 Shipments By Late 2024, Analyst Predicts</a>.</li>
</ul>

Analyst Color

Equities

Large Cap

Health Care

Trading Ideas

General

Hologic Adds Gynesonics' Sonata System In $350M Acquisition To Boost Fibroid Treatments

Hologic To Acquire Women's Health Medical Device Co. Gynesonics For ~$350M

Leerink Partners analyst Puneet Souda maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and lowers the price target from $95 to $90.

Leerink Partners Maintains Outperform on Hologic, Lowers Price Target to $90

10 analysts have shared their evaluations of Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Hologic, presenting an average target of $86.6, a high estimate of $95.00, and a low estimate of $78.00. Observing a 0.7% increase, the current average has risen from the previous average price target of $86.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728065025_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Hologic by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$82.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hologic compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Hologic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Hologic's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hologic analyst ratings.</a>
<h2>Unveiling the Story Behind Hologic</h2>
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
<h3>Hologic: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Hologic's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 2.74%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Hologic's net margin excels beyond industry benchmarks, reaching 19.23%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Hologic's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.97% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Hologic's ROA stands out, surpassing industry averages. With an impressive ROA of 2.21%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Hologic's debt-to-equity ratio is below the industry average at 0.52, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Hologic: Insights From 10 Financial Analysts

Mizuho analyst Anthony Petrone maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and raises the price target from $85 to $90.

Mizuho Maintains Outperform on Hologic, Raises Price Target to $90

Evercore ISI Group analyst Vijay Kumar maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a In-Line and raises the price target from $78 to $82.

Evercore ISI Group Maintains In-Line on Hologic, Raises Price Target to $82

Citigroup analyst Patrick Donnelly downgrades Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Buy to Neutral and lowers the price target from $95 to $85.

Downgrades

Citigroup Downgrades Hologic to Neutral, Lowers Price Target to $85

Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) has outperformed the market over the past 20 years by 6.54% on an annualized basis producing an average annual return of 14.96%. Currently, Hologic has a market capitalization of $18.77 billion. 
Buying $100 In HOLX: If an investor had bought $100 of HOLX stock 20 years ago, it would be worth $1,619.80 today based on a price of $80.82 for HOLX at the time of writing.
<h3>Hologic's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727719213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth $1,600 Today

Hologic (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holx#NASDAQ">HOLX</a>) has been gaining from new strategic product launches across Diagnostics and Breast Health. However, macroeconomic issues and unfavorable FX headwinds continue to impede growth. The stock carries a Zacks Rank #3 (Hold) currently.
<h2>Major Factors Driving HOLX Stock Growth</h2>
Among Hologic&#39;s advanced diagnostic products, primary revenue-generating ones are molecular diagnostic assays, which run on advanced instrumentation systems (Panther, Panther Fusion and Tigris), ThinPrep cytology system and the Rapid Fetal Fibronectin Test. With solid 10.5% growth, excluding COVID-19 sales in the fiscal third quarter of 2024, the Molecular Diagnostics business has consistently maintained high-single to double-digit gains in 13 of the last 15 quarters. Growth continues to be driven by the ongoing adoption and utilization of the broad menu in the Panther platform.
In Breast Health, Hologic expanded its product offering from imaging to cover the continuum of breast cancer care, including biopsy and surgery. The business is thriving primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment, with key profitable offerings such as 3D digital mammography systems, image analytics software utilizing artificial intelligence, ultrasound imaging and minimally invasive breast biopsy guidance systems. In the third quarter of fiscal 2024, revenues increased 7.1% (excluding the divested SSI business), driven by domestic and international growth of 7.2% and 12.1%, respectively.
The company&#39;s international sales have been a major catalyst in the past few years, growing 5.1% year over year in the third quarter of fiscal 2024. Molecular STI testing, cytology and MyoSure experienced strong growth in the global markets. However, the company perceives it as still in the early phase of utilizing its expanded Panther installed base. Similarly, while international cytology and STI testing have more dominant U.S. revenues, they are expected to become meaningful revenue drivers in the international markets with time.
In order to streamline its operations and reduce the cost of revenues, Hologic has adopted a few significant strategies over the past few years. The company has invested deliberately and opportunistically in commercial areas where management has recognized a good return. These include Hologic&#39;s Genius marketing campaign in Breast Health, cervical cancer co-testing initiatives in Diagnostics, along with efforts to gain competitive market share with NovaSure.
<div class="chart_embed">
<h2>Hologic, Inc. Price</h2>
<img alt="Hologic, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/2d/1727441408.png" style="height:251px; width:538px" title="" />
Hologic, Inc. price | Hologic, Inc. Quote
Per management, these strategic initiatives are already paying off through increased brand awareness, market share gains, and price stability, all of which will contribute to the company&#39;s higher sales. In the third quarter of fiscal 2024, the company was awarded the Innovative Technology Contract by Vizient, which expands access to its Surgical product lineup. The contract recognized Hologic&#39;s CoolSeal advanced energy portfolio and JustRight 5 mm stapler for their potential to enhance clinical care, patient safety and healthcare worker safety or improve business operations of healthcare organizations.
</div>
The stock has gained 12.2% year to date, compared with the industry&#39;s 7.6% rise. With the company currently focusing on the expansion of diagnostics assay and breast health offerings in global markets, we expect the stock to continue its upward movement in the coming days.
<h2>Major Downsides for HOLX</h2>
Continued concerns about the systemic impact of potential long-term and widespread recession have added to market volatility and diminished expectations for economic growth. The effect of the worldwide political and social uncertainty, including the impact on trade regulations and tariffs, economic disruptions as well as the ongoing supply chain constraints, have reportedly hampered the costs and sales of Hologic&#39;s products in certain countries in recent times. In the third quarter of fiscal 2024, Hologic&#39;s cost of revenues (product, service and other) rose about 1.9% year over year, while selling, general and administration expenses increased 4.2%.
These uncertainties surrounding global economic conditions and financial markets may cause medical equipment purchasers to decrease their medical health insurance premiums and procurement activities. Additionally, higher unemployment rates and health insurance premiums, co-payments and deductibles may result in cost-conscious consumers making fewer trips to their physicians and specialists, affecting the demand for the company&#39;s products and procedures.
We remain worried about the significant challenges Hologic faces owing to unfavorable foreign currency impact that has been adversely impacting the company&#39;s overall performance in the past few quarters. The company&#39;s international sales are often denominated in foreign currencies, including the euro, UK pound and renminbi. Changes in currency exchange rates, particularly the increase in the value of the dollar against any such foreign currencies, may reduce the reported value of Hologic&#39;s revenues outside the United States and associated cash flows. The company expects about $3 million adverse currency impact in the fourth quarter.
For several quarters in a row, declining COVID-19 assay revenues have been a headwind to some of the company&#39;s key performance metrics. Although the company returned to growth in the fiscal third quarter, the potential impact of the COVID-19 sales downturn still lingers.
Hologic&#39;s fiscal 2024 guidance assumes $70 million from COVID-19 assay sales, including $7 million in the fourth quarter of fiscal 2024. Overall, revenues from COVID-19-related items are expected to be approximately $105 million in fiscal 2024.
<h2>Key Picks</h2>
Some better-ranked stocks in the broader medical space are TransMedics Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>), AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and OrthoPediatrics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kids#NASDAQ">KIDS</a>). While TransMedics sports a Zacks Rank #1 (Strong Buy) at present, AxoGen and OrthoPediatrics carry a Zacks Rank #2 (Buy) each.
Estimates for TransMedics&#39; 2024 earnings per share have moved up 2.5% to $1.23 in the past 30 days. Shares of the company have soared 156.5% in the past year compared with the industry&#39;s 17.5% growth. TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for AxoGen&#39;s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 165.9% in the past year, compared with the industry&#39;s 17.6% growth. AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for OrthoPediatrics&#39; 2024 loss per share have declined to 92 cents from 96 cents in the past 30 days. In the past year, shares of KIDS have lost 17.1% against the industry&#39;s 20.8% growth. In the last reported quarter, it delivered an earnings surprise of 25.81%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.81%.
<a href="https://www.zacks.com/stock/news/2342713/holx-stock-gains-from-new-offerings-despite-macro-issues?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2342713">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

Government

Mid Cap

Regulations

Guidance

Offerings

Contracts

Small Cap

Management

Markets

AXGN

KIDS

TMDX

HOLX Stock Gains From New Offerings Despite Macro Issues

Ratings for Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $85.78, a high estimate of $95.00, and a low estimate of $76.00. This upward trend is apparent, with the current average reflecting a 0.92% increase from the previous average price target of $85.00.
<img src="https://www.benzinga.com/files/images/story/2024/1726578028_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Hologic. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$76.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$87.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Hologic compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Hologic's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Hologic's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hologic analyst ratings.</a>
<h2>Discovering Hologic: A Closer Look</h2>
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
<h3>Key Indicators: Hologic's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Hologic's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 2.74%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Hologic's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 19.23% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Hologic's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.97%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Hologic's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.21%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.52, Hologic adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Hologic Analyst Ratings: What You Need To Know

Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) has outperformed the market over the past 20 years by 6.49% on an annualized basis producing an average annual return of 14.78%. Currently, Hologic has a market capitalization of $18.58 billion. 
Buying $1000 In HOLX: If an investor had bought $1000 of HOLX stock 20 years ago, it would be worth $16,165.24 today based on a price of $80.01 for HOLX at the time of writing.
<h3>Hologic's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726149845_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Hologic Stock In The Last 20 Years

Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) has outperformed the market over the past 20 years by 6.49% on an annualized basis producing an average annual return of 14.78%. Currently, Hologic has a market capitalization of $18.58 billion. 
Buying $1000 In HOLX: If an investor had bought $1000 of HOLX stock 20 years ago, it would be worth $16,165.24 today based on a price of $80.01 for HOLX at the time of writing.
<h3>Hologic's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726149789_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) has outperformed the market over the past 20 years by 6.49% on an annualized basis producing an average annual return of 14.78%. Currently, Hologic has a market capitalization of $18.58 billion. 
Buying $1000 In HOLX: If an investor had bought $1000 of HOLX stock 20 years ago, it would be worth $16,165.24 today based on a price of $80.01 for HOLX at the time of writing.
<h3>Hologic's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726149744_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) has outperformed the market over the past 20 years by 6.49% on an annualized basis producing an average annual return of 14.78%. Currently, Hologic has a market capitalization of $18.58 billion. 
Buying $1000 In HOLX: If an investor had bought $1000 of HOLX stock 20 years ago, it would be worth $16,165.24 today based on a price of $80.01 for HOLX at the time of writing.
<h3>Hologic's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726149636_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hologic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NYSE">HOLX</a>) short percent of float has risen 10.56% since its last report. The company recently reported that it has 5.17 million shares sold short, which is 3.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Hologic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725291915_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hologic has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Hologic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Hologic's peer group average for short interest as a percentage of float is 4.47%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Hologic's Recent Short Interest

Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) has outperformed the market over the past 10 years by 1.79% on an annualized basis producing an average annual return of 12.59%. Currently, Hologic has a market capitalization of $18.90 billion. 
Buying $1000 In HOLX: If an investor had bought $1000 of HOLX stock 10 years ago, it would be worth $3,280.24 today based on a price of $81.36 for HOLX at the time of writing.
<h3>Hologic's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724094016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Hologic Stock In The Last 10 Years

Throughout the last three months, 8 analysts have evaluated Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Hologic and provided 12-month price targets. The average target is $85.25, accompanied by a high estimate of $95.00 and a low estimate of $76.00. Observing a 1.14% increase, the current average has risen from the previous average price target of $84.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1723824049_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Hologic is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$76.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$87.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hologic. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hologic compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Hologic's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Hologic's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hologic analyst ratings.</a>
<h2>Unveiling the Story Behind Hologic</h2>
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
<h3>Financial Insights: Hologic</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Hologic showcased positive performance, achieving a revenue growth rate of 2.74% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 19.23%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Hologic's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.97% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Hologic's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.21%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.52.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 8 Ratings For Hologic

RBC Capital analyst Conor McNamara reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Sector Perform and maintains $82 price target.

RBC Capital Reiterates Sector Perform on Hologic, Maintains $82 Price Target

MedTech stocks are at the forefront of revolutionizing healthcare with the dynamic growth potential of technology. Amid this backdrop, it could be wise to consider investing in companies like Medtronic (MDT), STERIS (STE), and Hologic (HOLX), which are transforming the way healthcare is delivered and tailoring it to individual patient needs. Read more… As innovation continues to shape nearly every industry, the medical sector is no exception. Now, you might wonder how the technology can influence the medical industry. The MedTech sector is innovating across various areas, including medical devices, diagnostics, digital health platforms, and robotic surgery.
These technological breakthroughs are creating unique opportunities for investors to invest in fundamentally sound companies like Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>), STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>), and Hologic, Inc. (<a href="https://stocknews.com/stock/HOLX/">HOLX</a>), which are innovating and advancing life-saving devices.
Over the past few years, the MedTech sector has experienced explosive growth, reshaping the healthcare industry in ways we never imagined, and it's showing no signs of slowing down. From $456.9 billion in 2020, the MedTech market is expected to soar to <a href="https://www.alpha-sense.com/blog/trends/medtech-trends-outlook/">$800 billion by 2030</a>. It's not just the numbers that are growing; healthcare companies are increasingly merging with MedTech firms to enhance their capabilities and gain a competitive edge.
Moreover, AI has been a game-changer in MedTech, driving breakthroughs in predictive diagnostics, remote monitoring, and precision medicine. With these advancements, the global market for medical devices is forecasted to <a href="https://www.globaldata.com/media/medical-devices/ai-to-drive-medical-devices-industry-to-1-2-billion-in-2027-forecasts-globaldata/">hit $1.2 billion</a> by 2027, exhibiting a CAGR of 29.1%.
Several factors fuel the growth of MedTech stocks, including an aging global population, the rising prevalence of chronic diseases, and a strong push toward digital transformation. As demand for more effective, efficient, and accessible healthcare solutions increases, MedTech companies are well-positioned to capitalize on these trends, making them a compelling investment opportunity for investors.
Considering these conducive trends, let's examine the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry stocks in detail, beginning with the third choice:
Stock #3: Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>)
Headquartered in Dublin, Ireland, MDT provides healthcare technology solutions. It develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The company operates through four segments: Cardiovascular Portfolio; Neuroscience Portfolio; Medical Surgical Portfolio; and Diabetes Operating Unit.
On August 15, the company's board of directors approved a second-quarter dividend of $0.70 per share for fiscal year 2025, consistent with the company's previous dividend increase announced in May. The dividend will be paid on October 11, 2024, to shareholders of record as of September 27, 2024.
As a member of the S&amp;P 500 Dividend Aristocrats, MDT has raised its annual dividend for 47 consecutive years. It pays an annual dividend of $2.80 per share, which translates to a yield of 3.13% on the prevailing share price. Also, its four-year average dividend yield is 2.75%.
On August 7, MDT announced that the U.S. Food and Drug Administration (FDA) approved its Simplera&#x2122; continuous glucose monitor (CGM). It is the company's first disposable, all-in-one CGM, which is half the size of previous models and easier to use.
Additionally, the company revealed a global partnership with Abbott to create an integrated CGM based on Abbott's latest technology, exclusively compatible with MDT's smart insulin device. The company will sell this system exclusively and expects the partnership to boost its Diabetes revenue while maintaining its gross margin.
MDT's net sales for the first quarter (ended July 26, 2024) increased 2.8% year-over-year to $7.92 billion. Its non-GAAP operating profit grew 2.3% from the prior year's quarter to $1.95 billion. The company's attributable net income rose 31.7% from the year-ago value to $1.04 billion, while its non-GAAP <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> stood at $1.23, up 2.5% year-over-year.
The company has updated its fiscal year 2025 outlook, increasing its revenue growth projection to a range of 4.5% to 5%, up from the previous estimate of 4% to 5%. Additionally, it has adjusted its non-GAAP EPS guidance to a new range of $5.42 to $5.50, slightly higher than the prior forecast of $5.40 to $5.50. This revised guidance suggests a 4% to 6% growth in non-GAAP EPS.
The consensus revenue estimate of $8.41 billion for the fiscal third quarter (ending January 2025) represents a 3.9% increase year-over-year. The consensus EPS estimate of $1.37 for the same quarter indicates a 5.6% improvement year-over-year. The company has an impressive surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Over the past nine months, the stock has surged 13.5%, closing the last trading session at $89.39.
MDT's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
MDT has a B grade for Stability. It is ranked #19 out of 132 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. <a href="https://stocknews.com/stock/MDT/">Click here</a> to see the additional ratings for MDT (Growth, Value, Momentum, Sentiment, and Quality).
Stock #2: STERIS plc (<a href="https://stocknews.com/stock/STE/">STE</a>)
STE is a provider of products and services that support patient care with an emphasis on infection prevention worldwide. It operates through three segments: Healthcare; Applied Sterilization Technologies (AST); and Life Sciences. 
On July 31, buoyed by strong financial performance, the company increased its quarterly interim dividend by $0.05 to $0.57 per share, payable to its shareholders on September 20, 2024.
With 19 years of consecutive dividend growth, STE pays an annual dividend of $2.28, which translates to a yield of 0.95% at the current share price. Its four-year average dividend yield is 0.86%. Moreover, the company's dividend payouts have increased at an impressive CAGR of 9.3% over the past three years.
For the first quarter of 2024, which ended on June 30, STE's total revenues increased 8.1% year-over-year to $1.28 billion, while its gross profit stood at $572.43 million, up 8.2% year-over-year. Its net income attributable for the quarter amounted to $145.40 million or $1.46 per share, representing an increase of 17.7% and 16.8%, respectively, from the same period last year. Also, the company's net cash flow from operating activities grew 8% from the year-ago value to $303.74 million.
As per the updated guidance for the fiscal year 2025, STE forecasts revenue from continuing operations to increase 6.5% to 7.5% from 2024. The company also expects adjusted EPS from continuing operations between $9.05 and $9.25 and free cash flow to be approximately $700 million.
Analysts expect STE's revenue for the fiscal year ending March 2025 to grow marginally year-over-year to $5.50 billion, while its EPS for the same period is expected to increase 3.8% from the prior year to $9.16.
STE shares have surged 20.4% over the past nine months to close the last trading session at $239.05.
STE's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
It also has a B grade for Growth, Stability, and Sentiment. Within the same industry, it is ranked #13 out of 132 stocks. <a href="https://stocknews.com/stock/STE/">Click here</a> to see STE's ratings for Value, Momentum, and Quality.
Stock #1: Hologic, Inc. (<a href="https://stocknews.com/stock/HOLX/">HOLX</a>)
HOLX is a medical technology company focused on improving women's health and well-being through early detection and treatment. It is a developer, manufacturer, and supplier of diagnostics products, medical imaging systems, and surgical products worldwide. The company operates through four segments: Diagnostics; Breast Health; GYN Surgical; and Skeletal Health.
On July 25, HOLX acquired Endomagnetics Ltd., a privately held UK-based developer of breast cancer surgery technologies, for $310 million. This acquisition enhances access to Endomag's innovative technologies, diversifying HOLX's expanding interventional breast health portfolio.
In the fiscal third quarter that ended on June 29, 2024, HOLX's total revenue increased 2.7% year-over-year to $1.01 billion with a non-GAAP gross margin of 61.1% (up 30 bps year-over-year). The company reported income from operations of $244 million, indicating a significant growth from the prior year quarter. Its adjusted EBITDA increased 8.5% year-over-year to $338.50 million.
HOLX's non-GAAP net income came in at $250.70 million, up 8.4% year-over-year, while its non-GAAP EPS grew 14% from the year-ago value to $1.06.
For the fourth quarter of the fiscal year 2024, the company's revenue is projected to be between $970 million and $985 million, with EPS anticipated to fall between $0.80 and $0.87. On a consolidated adjusted basis, its non-GAAP EPS is expected to range from $0.97 to $1.04.
Street expects HOLX's revenue for the fiscal fourth quarter (ending September 2024) to increase 3.4% year-over-year to $977.72 million. Its EPS for the same period is expected to register a 13.8% growth from the prior year, settling at $1.01. In addition, it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters, which is promising.
Shares of HOLX have gained 16.9% over the past nine months to close the last trading session at $80.99.
It's no surprise that HOLX has an overall rating of B, equating to a Buy in our POWR Ratings system. It has a B grade for Growth and Quality. Out of 132 stocks in the Medical - Devices &amp; Equipment industry, HOLX is ranked #10.
Beyond what is stated above, we've also rated HOLX for Value, Momentum, Stability, and Sentiment. Get all HOLX ratings <a href="https://stocknews.com/stock/HOLX/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
MDT shares were trading at $89.88 per share on Friday afternoon, up $0.49 (+0.55%). Year-to-date, MDT has gained 10.98%, versus a 14.67% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/mdt-ste-holx-3-medtech-stocks-revolutionizing-healthcare/>3 MedTech Stocks Revolutionizing Healthcare</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 MedTech Stocks Revolutionizing Healthcare

Hologic authorizes $1.5B buyback of common stock

Michael Matson, an analyst from Needham, maintained the Buy rating on Hologic (HOLX – Research Report). The associated price target remains the sam...

Hologic: A Buy Rating Amidst Temporary Challenges and Growth Potential

Quantifying The S&P 500's Exposure To Artificial Intelligence

Bio-Rad upped by Citi to buy; Charles River, Hologic downgraded

The medical industry is on the fence of explosive growth, fueled by technological advancements. In this evolving landscape, investors could consider investing in promising medical device stocks like Hologic, Inc. (HOLX), Avanos Medical (AVNS), and Embecta Corp. (EMBC) with solid growth prospects. Learn more… Thanks to cutting-edge technology, medical stocks are effectively reshaping the healthcare sector. The industry is experiencing significant growth, driven by increasing demand for advanced healthcare solutions, particularly in diagnostics, surgeries, and patient monitoring.
Given this backdrop, investors looking for growth opportunities could take a look at these three fundamentally robust medical device stocks: Hologic, Inc. (<a href="https://stocknews.com/stock/HOLX/">HOLX</a>), Avanos Medical, Inc. (<a href="https://stocknews.com/stock/AVNS/">AVNS</a>), and Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>). These companies are shaping healthcare delivery's future and benefitting from technological advancements.
The medical devices industry is poised for steady growth as its market size is anticipated to reach <a href="https://www.mordorintelligence.com/industry-reports/global-medical-device-technologies-market-industry?network=g&amp;source_campaign=&amp;utm_source=google&amp;utm_medium=cpc&amp;matchtype=b&amp;device=c&amp;gad_source=1&amp;gclid=Cj0KCQjwpP63BhDYARIsAOQkATb9SdZ7QZMMYB0trPXq_zr3V73FHtcX5g9Z7xWnrv4R67MwdKzHOV0aApKdEALw_wcB">$893.07 billion by 2029</a>, exhibiting a CAGR of 7%. Moreover, by 2030, the global annual medical device sales are forecasted to <a href="https://kpmg.com/us/en/articles/2023/medical-devices-2030.html#:~:text=The%20medical%20device%20industry%20is,US%24800%20billion%20by%202030%20.">hit $800 billion</a>.
Moreover, innovations like AI-powered diagnostic tools, wearable health devices, and robotic surgery systems are revolutionizing patient care. The FDA has already authorized <a href="https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices#:~:text=the%20FDA%20has%20authorized%20950%20AI/ML%2Denabled%20medical%20devices.">950 AI/ML-enabled medical devices</a>, which promise faster diagnoses, more precise treatments, and improved patient outcomes.
Considering these favorable trends, let's look at the fundamentals of the above-mentioned <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> picks in detail:
Stock #3: Hologic, Inc. (<a href="https://stocknews.com/stock/HOLX/">HOLX</a>)
HOLX is a medical technology company focused on improving women's health and well-being through early detection and treatment. It is a developer, manufacturer, and supplier of worldwide diagnostics, medical imaging systems, and surgical products. The company operates through four segments: Diagnostics; Breast Health; GYN Surgical; and Skeletal Health.
On July 25, HOLX acquired Endomagnetics Ltd., a privately held UK-based developer of breast cancer surgery technologies, for $310 million. This acquisition enhances access to Endomag's innovative technologies and diversifies HOLX's expanding interventional breast health portfolio.
In the fiscal third quarter that ended on June 29, 2024, HOLX's total revenue increased 2.7% year-over-year to $1.01 billion with a non-GAAP gross margin of 61.1% (up 30 bps year-over-year). The company reported income from operations of $244 million, indicating a significant growth from the prior year quarter.
In addition, its adjusted EBITDA increased 8.5% year-over-year to $338.50 million. HOLX's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> came in at $250.70 million, up 8.4% year-over-year, while its non-GAAP EPS grew 14% from the year-ago value to $1.06.
For the fourth quarter of the fiscal year 2024, the company's revenue is projected to be between $970 million and $985 million, with non-GAAP EPS anticipated to fall between $0.97 and $1.04.
The consensus revenue estimate of $977.49 million for the fiscal fourth quarter (ended September 2024) represents a 3.4% increase year-over-year. The consensus EPS estimate of $1.01 for the same quarter indicates a 13.9% improvement year-over-year. The company has an impressive surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Over the past three and five years, HOLX's total assets grew at CAGRs of 1.2% and 6.4%, respectively. Also, the company's normalized net income and operation income (EBIT) have increased at a CAGR of 16.8% and 10.9%, respectively, over the past five years.
Shares of HOLX have gained 14.3% over the past year to close the last trading session at $79.22.
HOLX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
HOLX has a B grade for Growth and Quality. It is ranked #14 out of 134 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. <a href="https://stocknews.com/stock/HOLX/">Click here</a> to see the additional ratings for HOLX (Value, Momentum, Stability, and Sentiment).
 Stock #2: Avanos Medical, Inc. (<a href="https://stocknews.com/stock/AVNS/">AVNS</a>)
AVNS is a medical device company that focuses on delivering medical device solutions. The company conducts its business in one segment, which provides its medical device products to healthcare providers and patients globally with manufacturing facilities.
AVNS' net sales for the second quarter (ended June 30, 2024) increased marginally year-over-year to $171.70 million. Its non-GAAP operating profit from continuing operations grew 18.5% from the prior year's quarter to $21.80 million. The company's net income stood at $1.80 million compared to the prior-year quarter's loss of $68.10 million, while its EPS came in at $0.04 versus a loss of $1.46 per share last year.
In addition, AVNS' adjusted EBITDA from continuing operations rose 17% from the year-ago value to $26.80 million. Its free cash flow came in at $21.90 million compared to a year-ago net loss of $6.6 million.
As per the fiscal year 2024 outlook, AVNS forecasts revenue from continuing operations to range between $685 million and $705 million. The company also expects adjusted EPS from continuing operations between $1.30 and $1.45 and adjusted gross margins from continuing operations to fall in the range of 59.5%-60.5%.
Street expects AVNS' revenue for the fiscal third quarter (ended September 2024) to increase 2.4% year-over-year to $175.33 million. Its EPS for the same period is expected to register a 17.8% growth from the prior year, settling at $0.35. In addition, it surpassed the consensus revenue in each of the trailing four quarters, which is promising.
Moreover, AVNS' EBITDA and net income have grown at CAGRs of 32.7% and 47.5%, respectively, over the past three years. In addition, its EPS increased at 60.6% CAGR over the same time frame.
Over the past three months, the stock has surged 18.5%, closing the last trading session at $23.02.
It's no surprise that AVNS has an overall rating of B, equating to a Buy in our POWR Ratings system. It has an A grade for Growth and a B for Value. Out of 134 stocks in the same industry, AVNS is ranked #12.
Beyond what is stated above, we've also rated AVNS for Momentum, Stability, Sentiment, and Quality. Get all AVNS ratings <a href="https://stocknews.com/stock/AVNS/">here</a>.
Stock #1: Embecta Corp. (<a href="https://stocknews.com/stock/EMBC/">EMBC</a>)
EMBC is a global diabetes care company focusing on providing various solutions to enhance the health and well-being of people with diabetes. It has a portfolio of products that include pen needles, syringes, safety injection devices, and digital applications to assist people with managing patient's diabetes. 
On September 3, EMBC received clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system, required for adults who require insulin, both type 1 (T1D) and type 2 (T2D) diabetes, to be managed. This clearance aligns with the company's vision and focuses on developing a patch pump, addressing obstacles to adopting pump therapy for people who use insulin daily to manage their diabetes. 
For the third quarter of 2024, which ended on June 30, EMBC's revenue stood at $272.50 million. Its adjusted operating income grew 4.4% from the year-ago value to $83.30 million. Its adjusted net income for the quarter amounted to $43 million or $0.74 per share, representing an increase of 8% and 7.2%, respectively, from the same period last year. Also, the company reported an adjusted EBITDA of $99.20 million, indicating a 15.5% growth from the prior year's quarter.
The company has updated its fiscal year 2024 financial guidance, increasing its adjusted gross margin projection to a range of 65.25% to 65.50%, up from the previous estimate of 64.5% to 65%. Additionally, it adjusted its non-GAAP EPS guidance to a new range of $2.30 to $2.35, slightly higher than the prior forecast of $2.20 to $2.30.
Moreover, its adjusted EBITDA margin is expected to range between 31.25%-31.50%, an increase from the previous estimate of 31%-31.5%. Meanwhile, EMBC projects its revenue to fall in the range of $1.11 billion to $1.12 billion.
Analysts expect EMBC's revenue and EPS for the current year (ending September 2024) to be $1.11 billion and $2.39, respectively. For the fiscal year 2025, its revenue is expected to grow marginally from the prior year to $1.12 billion, and its EPS is projected to come in at $2.27.
Over the past year, EMBC's net income has increased at a CAGR of 47.7%, while its EPS grew at 45.3% CAGR.
EMBC shares have surged 10.1% over the past three months to close the last trading session at $13.29.
EMBC's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Value and Quality and a B for Growth. Within the Medical - Devices &amp; Equipment industry, it is ranked #3. <a href="https://stocknews.com/stock/EMBC/">Click here</a> to see EMBC's ratings for Momentum, Stability, and Sentiment.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
HOLX shares were trading at $79.88 per share on Friday morning, up $0.66 (+0.83%). Year-to-date, HOLX has gained 11.80%, versus a 20.77% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/holx-avns-embc-3-medical-device-stocks-with-strong-growth-prospects/>3 Medical Device Stocks With Strong Growth Prospects</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Medical Device Stocks With Strong Growth Prospects

Puneet Souda, an analyst from Leerink Partners, maintained the Buy rating on Hologic (HOLX – Research Report). The associated price target was lowe...

Buy Rating Maintained for Hologic Amidst Recovery and Strong Capital Management

Hologic to acquire Gynesonics

Needham analyst Michael Matson has maintained their bullish stance on HOLX stock, giving a Buy rating on October 7. Michael Matson has given his Bu...

Hologic's Strategic Acquisition of Gynesonics Bolsters Market Position: A Buy Rating by Michael Matson

In a report released yesterday, Casey Woodring from J.P. Morgan maintained a Buy rating on Hologic (HOLX – Research Report), with a price target of...

J.P. Morgan Sticks to Its Buy Rating for Hologic (HOLX)

AFMC

AMZN

ANET

ANEW

ARKK

ARKQ

ARTY

AVNS

BBMC

BFOR

BKMC

BMVP

BOTZ

BOUT

CDNS

DDIV

DEUS

DTEC

DVLU

EMBC

EQAL

ETHO

FFSM

FFTY

FLQM

FOVL

FRTY

FSCS

FSMD

FTDS

FTNT

GOOG

GOOGL

GRPM

HAIL

HLGE

HOMZ

IGPT

IMCB

IMCG

IMCV

INTC

IVOG

IVOO

IVOV

JHMM

JPME

JSMD

KOMP

LRNZ

LSAT

MDYG

MDYV

MIDE

MSFT

NUMG

NUMV

NVDA

ONEO

ONEV

ONEY

PAMC

PANW

PEXL

PTMC

QMOM

QQQJ

QQQN

QVAL

QVMM

REGL

ROBO

ROBT

RSPT

SCHM

SDVY

SFYX

SIXL

SMDY

SNPS

SPMD

SQEW

SYLD

THNQ

TMDV

TPHD

TPLC

TSLA

UBOT

UPGD

USMF

VFMF

VFMO

VFMV

VFQY

VFVA

VRAI

VUSE

WBIY

WTAI

XMHQ

XMLV

XMMO

XMVM

Press Releases

Hologic to Webcast Presentations at Upcoming Investor Conferences

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2024 on Monday, July 29, 2024

72 Million American Women Have Skipped or Delayed Vital Screenings

Hologic Completes Acquisition of Endomagnetics Ltd

Hologic Announces Financial Results for Third Quarter of Fiscal 2024

Hologic to Webcast Presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference

Hologic Unveils #BustTheMyth Campaign to Debunk Breast Cancer Myths and Empower Women This Breast Cancer Awareness Month

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2024 on Monday, November 4, 2024

Hologic to Acquire Gynesonics, Developer of Minimally Invasive Solutions for Women's Health

Opinion

Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

ATOS

KZIA

Comments

Hologic

Notizie

Ultime notizie per Hologic (NASDAQ:HOLX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO